Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16597155 | 0.87 | NPC1 (0.66) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL16597154 | 0.85 | NPC1 (0.64) | NPC1RAB9AHTTSMN1; SMN2POLB | |
| SCHEMBL16986158 | 0.81 | TSHR (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL9557074 | 0.81 | TAAR1 (0.68) | NPC1SMN1; SMN2ALDH1A1FKBP1AKMT2A | |
| Hydrochloric Acid SCHEMBL16986155 | 0.80 | TSHR (0.72) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13345791 | 0.78 | NAAA (0.68) | NPC1RAB9A | |
| SCHEMBL524458 | 0.78 | KDM4E (0.56) | NPC1SMN1; SMN2ALDH1A1FKBP1ATAAR1 | |
| SCHEMBL524333 | 0.78 | KDM4E (0.56) | NPC1SMN1; SMN2ALDH1A1FKBP1ATAAR1 | |
| SCHEMBL523656 | 0.78 | KDM4E (0.56) | NPC1SMN1; SMN2ALDH1A1FKBP1ATAAR1 | |
| SCHEMBL12123771 | 0.78 | ALDH1A1 (0.73) | HTTALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414529-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | Matrix Laboratories Ltd (IN) | 2012-02-08 | — | — | EP | claimed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | claimed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | claimed |
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010113175-A3 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
| WO-2007017705-A1 | PROCESS FOR THE PREPARATION OF AZETIDINONES | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | CES1, CMA1, CYP51A1 | NPC1 399/4885RAB9A 3117/4885HTT 1841/4885 |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | TPSD1, PCSK9, PEPD | NPC1 581/4885RAB9A 3657/4885HTT 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.